Clinical trial
Adverse Outcomes and Mortality in Liver Transplant
Recruiting now · Not applicable · 1 countries · Registry ID NCT05477277
What this study is about
Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.
Basic eligibility
Full registry criteria
Treatments and study arms
MAsS
Add MAsS to standard of care MRI scan
Primary outcomes
The MAsS is a composite score of muscle fat index (% of muscle fat normalized to sex, weight in kg and height in meters) and muscle volume index (muscle volume in liters normalized to patient sex, height in meters and weight in kg)
Number of pre- and post-transplant inpatient days
Number of pre- and post-transplant ICU days
Number of days alive outside of the hospital in the first year after liver transplant
Mortality within the first year after liver transplant
In patients who remain on the waitlist, serial MAsS measurements (see Outcome 1) will be taken and changes over time will be assessed
Study locations
1 locations were listed when this page was built. The first 40 are shown.